25508-20-7

Usage

Uses

Used in Pharmaceutical Industry:
1,3-BIS(BENZYLOXYCARBONYL)-2-METHYL-2-THIOPSEUDOUREA is used as a synthetic building block for the preparation of Leucetta alkaloids. These alkaloids are known for their diverse biological activities, including anticancer, antiviral, and anti-inflammatory properties. The compound's unique structure allows for the development of new Leucetta alkaloid derivatives with potential therapeutic applications.
1,3-BIS(BENZYLOXYCARBONYL)-2-METHYL-2-THIOPSEUDOUREA is also used as a reactant in the synthesis of complex molecular structures through tandem oxidative dearomatizing spirocyclizations. This method allows for the efficient construction of intricate molecular frameworks, which can be further modified and optimized for specific pharmaceutical applications.

InChI:InChI=1/C18H18N2O4S/c1-25-16(19-17(21)23-12-14-8-4-2-5-9-14)20-18(22)24-13-15-10-6-3-7-11-15/h2-11H,12-13H2,1H3,(H,19,20,21,22)

Upstream product

• 10049-21-5 sodium dihydrogenphosphate 
• 1885-14-9 phenyl chloroformate 
• 501-53-1 benzyl chloroformate 
• 867-44-7 S-Methylisothiourea sulfate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 14527-26-5 2-methylisothiourea sulphate 
• 31139-36-3 dibenzyl dicarbonate 
• 147895-43-0 S-methylisothiourea hemisulphate 
• 2986-19-8 carbamimidothioic acid methyl ester 

Downstream Products

• 195204-15-0 N-(t-butoxycarbonyl)-3-[3-piperidyl-(N-guanidino (bis-benzyloxycarbonyl))]-L-alaninol 
• 322474-27-1 C₂₉H₃₁F₃N₄O₈ 
• 195196-06-6 3-difluoromethyl-3-(tert-butoxycarbonylamino)piperidin-2-one 
• 322474-28-2 C₃₀H₃₄F₂N₄O₈ 
• 232607-84-0 [[(E)-Benzyloxycarbonylimino]-(3-{(S)-3-hydroxy-2-[2-((S)-2-oxo-3-phenylmethanesulfonylamino-azepan-1-yl)-acetylamino]-propyl}-piperidin-1-yl)-methyl]-carbamic acid benzyl ester 
• 221110-60-7 (S)-4-{(S)-2-[(S)-2-(1-{Benzyloxycarbonylamino-[(E)-benzyloxycarbonylimino]-methyl}-piperidin-3-yl)-1-hydroxymethyl-ethylcarbamoyl]-pyrrolidin-1-yl}-4-oxo-3-(2-propyl-pentanoylamino)-butyric acid methyl ester 
• 219519-90-1 1-(benzyloxycarbonylamino(benzyloxycarbonylimino)methyl)piperidine-3-carboxylic acid 
• 169605-45-2 (S)-3-{[3-(1-{Benzyloxycarbonylamino-[(Z)-benzyloxycarbonylimino]-methyl}-piperidin-4-ylmethoxy)-isoxazole-5-carbonyl]-amino}-2-butoxycarbonylamino-propionic acid methyl ester 

Relevant academic research and scientific papers

Reagents for Efficient Conversion of Amines to Protected Guanidines

Two new guanidinylation reagents, N,N′-bis(ortho-chloro-Cbz)-S- methylisothiourea and N,N′-bis(ortho-bromo-Cbx)-S-methylisothiourea, were compared with the already known N,N′-bis(Boc)-S-methylisothiourea and N,N′-bis(Cbz)-S-methylisothiourea. The new reagents proved to be superior to the known reagents. The reactions with all the new reagents were accelerated by addition of DMAP. N,N′-Bis(ortho-chloro-Cbz)- and N,N′-bis(ortho- bromo-Cbz)guanidines are stable when treated with trifluoroacetic acid and can be converted to guanidines by hydrogenolysis.

Selective carbamate conversion of protected guanidines

The reactivity of carbamates to produce other carbamates (by reaction with alcohols) or amidinoureas (by reaction with amines), without the use of strong bases or catalysts, has been studied indicating the suitability/selectivity of the method in achievin

IMAGE-GUIDED ENERGY DEPOSITION FOR TARGETED DRUG DELIVERY

Disclosed are compositions and methods for targeted drug delivery using image-guided energy deposition to help localize active compounds to particular sites within the body of an animal. Also provided are compounds and formulations thereof for use in the

THIOPHENE -2- CARBOXYLIC ACID - (1H - BENZIMIDAZOL - 2 YL) - AMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE TEC KINASE ITK (INTERLEUKIN -2- INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS

Disclosed are compounds of formula (I): wherein Ar1, Ar2, R1, R2, R3, R4 and Xa are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for

Compounds with antiparasitic activity and medicines containing same

The invention relates to compounds having an anti-parasitic, in particular antimalarial activity, characterized in that they correspond to general formula (I) Applications in particular as compounds with anti-parasitic activity.

Efficient synthesis of (S)-(-)- and (R)-(+)-enantiomers of 15-deoxyspergualin (15-DSG)

An efficient synthesis of the (S)-(-)- and (R)-(+)-enantiomers of 15-deoxyspergualin (15-DSG) is reported. The synthesis involves preparative HPLC separation and subsequent hydrogenolysis of two diastereoisomers 10a and 10b of fully protected 15-DSG penultimates. Alternatively, diastereomerically pure amide 10b (97% de) was also prepared from acid 8b (97% de), which was obtained via crystallization of a 1:1 diastereomeric mixture of 8a and 8b. Copyright (C) 2000 Elsevier Science Ltd.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the Formula IX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

Preparation of optically active (S)-(-) and (R)-(+)-deoxyspergualin and novel intermediates thereof

A process for preparing optically active (S)-(-) and (R)-(+)-deoxyspergualin and salts thereof of the formula I STR1 by reacting a compound of formula II STR2 with a compound of formula III STR3 in the presence of a condensing/dehydrating agent and an org

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.

ANTITHROMBOTIC AGENTS

This invention relates to thrombin inhibiting compounds having the FormulaIX--Y--NH--(CH 2) r--G I where X, Y, r and G have the values defined in the description, as well as pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors, and thromboembolic disorder agents.